Skip to main content
Premium Trial:

Request an Annual Quote

GenMark to Net $39.3M from Public Offering

NEW YORK (GenomeWeb News) – GenMark Diagnostics late on Wednesday priced its public offering of 10 million shares at $4.20 per share.

The offering, which was announced on Tuesday, is expected to close on June 26. The firm expects to raise net proceeds of $39.3 million.

Those funds will go toward R&D work to expand the Carlsbad, Calif.-based molecular diagnostic firm's test menu and to further develop its NexGen System, a sample-to-answer platform. It will also be used to expand the company's US and global commercialization operations.

JP Morgan is the sole book-running manager on the offering. William Blair & Co. and Canaccord Genuity are co-managers. The underwriters have a 30-day option to purchase up to an additional 1.5 million shares to cover any over-allotments.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.